Stockpolly
Search
Delisting risk
SYBX · NASDAQ · Biotechnology

Synlogic (SYBX)

Former synthetic biology drug developer now seeking strategic alternatives.

$1.20
At close−0.02 (−1.64%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue030000000000
Cost of revenue111000000000
Gross profit−11−1000000000
12129312111211
Research & development91072−10000000
322111111111
Selling & marketing00−1000000000
General & administrative003011111111
Other expenses000000000000
Operating income−13−11−11−3−1−2−1−1−1−2−1−1
1−4−2161110−1320
Interest income111000000000
Other non-operating income−1421−6−1−1000−100
Income before tax−12−15−3230−10−1−221−1
Income tax expense000000000000
Net income from continuing operations−12−15−3230−10−1−221−1
Net income−12−15−3230−10−1−221−1
EPS, basic−$2.57−$1.71−$2.60$0.16−$0.01−$0.06$0.03−$0.04−$0.19$0.13$0.05−$0.04
EPS, diluted−$2.57−$1.71−$2.60$0.16−$0.01−$0.06$0.03−$0.04−$0.19$0.13$0.05−$0.04
Weighted average shares, basic5912121212121212121212
Weighted average shares, diluted5912121212121212121212
EBITDA−11−13−30310−1−1−1−1−1−1
Depreciation & amortization111011000000
EBIT−12−15−3230−1−1−1−1−1−1−1